Bioretec Oy
OMXH:BRETEC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
GameStop Corp
NYSE:GME
|
US |
Bioretec Oy
Total Equity
Bioretec Oy
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bioretec Oy
OMXH:BRETEC
|
Total Equity
€9.8m
|
CAGR 3-Years
72%
|
CAGR 5-Years
48%
|
CAGR 10-Years
N/A
|
|
|
R
|
Revenio Group Oyj
OMXH:REG1V
|
Total Equity
€114.7m
|
CAGR 3-Years
8%
|
CAGR 5-Years
10%
|
CAGR 10-Years
22%
|
|
|
M
|
Modulight Oyj
OMXH:MODU
|
Total Equity
€44.7m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
O
|
Optomed Oyj
OMXH:OPTOMED
|
Total Equity
€24m
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
N
|
Nexstim Oyj
OMXH:NXTMH
|
Total Equity
€4.2m
|
CAGR 3-Years
1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
2%
|
|
|
B
|
Biohit Oyj
OMXH:BIOBV
|
Total Equity
€14.9m
|
CAGR 3-Years
26%
|
CAGR 5-Years
11%
|
CAGR 10-Years
2%
|
|
Bioretec Oy
Glance View
Bioretec Ltd. develops bioabsorbable and bioresorbable implants for pediatric and adult orthopaedics. The company is headquartered in Tampere, Lansi-Suomen. The company went IPO on 2021-09-28. The firm operates as a developer, manufacturer and commercializer of innovative bioresorbable orthopedic implants and implant materials used for the treatment of bone and soft tissue injuries. Bioretec Oy’s existing Activa product portfolio consists of bioabsorbable biopolymer products that are alreadyavailable in the market for applications in pediatrics, trauma surgery as well as sports surgery. Bioretec Oy has one Germany-based subsidiary, BRI.Tech GmbH. The Company’s products are used all over the world.
See Also
What is Bioretec Oy's Total Equity?
Total Equity
9.8m
EUR
Based on the financial report for Dec 31, 2025, Bioretec Oy's Total Equity amounts to 9.8m EUR.
What is Bioretec Oy's Total Equity growth rate?
Total Equity CAGR 5Y
48%
Over the last year, the Total Equity growth was 0%. The average annual Total Equity growth rates for Bioretec Oy have been 72% over the past three years , 48% over the past five years .
